Celgene beats on Revlimid sales, raises 2018 forecast

Celgene Corp topped Wall Street estimates for quarterly profit on Thursday, helped by higher demand for its blockbuster cancer drug Revlimid, and the U.S. drugmaker raised its full-year earnings forecast. … …read more

Source:: Yahoo Finance

Discover Tomorrow’s Winning Stocks!
Get our latest stock reports before everyone else! Actionable news, and breakout stocks w multi-bagger upside potential — delivered directly to your inbox.
Your privacy is our priority. Your email address will never be sold or shared with anyone else.